Long-term cardiology side effects of antitumor therapy in patients with hemoblastosis

The relevance of improving diagnostic methods, drug and radiation therapy contributes to an increase in the life expectancy of cancer patients including hemoblastosis. At the same time, the number of patients with various complications, including those from the cardiovascular system as a result of antitumor therapy, has increased. The identification of long-term toxic effects of antitumor therapy in patients with hemoblastosis is relevant due to the increased life expectancy of patients after treatment. Objective: according to the literature, to evaluate the long-term side effects of cardiotoxic effects in patients with hemoblastosis who received antitumor treatment. Material and methods. When writing a literature review, data were analyzed in specialized medical databases Pubmed, Scopus, Web of Science in patients with hemoblastosis from 1994 to 2024. Results. Cardiotoxic side effects in patients with hemoblastosis as a result of antitumor therapy may occur in the long term years after treatment. This review is devoted to the analysis of the cardiotoxic effects of various forms of therapy on the heart in adults and children with hemoblastosis in the long-term period after treatment. The causes of side effects on the cardiovascular system are discussed, the molecular, genetic, and biochemical correlates of these disorders are described, and ways to prevent complications are considered. This, in turn, opens up opportunities for early detection and treatment of long-term complications in surviving patients. This will contribute to improving the quality of life of patients.